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Abstract: Around 80% of mutations in the PTEN gene have been reported to be associated 
with diseases such as Cowden syndrome, which is an autosomal dominant disorder associated 
with an increased risk of developing breast, thyroid, and endometrial neoplasms. Recent studies 
have also demonstrated that KILLIN, which is located proximally to PTEN, shares the same 
transcription start site, and is assumed to be regulated by the same promoter, but is transcribed 
in the opposite direction. In this regard, we postulate that there may be a connection between 
KILLIN/PTEN genes and breast and thyroid cancers. Using real-time quantitative polymerase 
chain reaction (qPCR), we found that expression of KILLIN, but not PTEN, was significantly 
decreased in 23 Chinese women with a personal history of breast and thyroid cancer or a personal 
history of breast cancer and a family history of thyroid cancer, or vice versa, and at least two 
persons in the family with thyroid cancer or at a young age ,40 years, when compared with 
healthy controls (P,0.0001). No PTEN mutations were found in these 23 patients. We then 
developed a simple methylation-sensitive restriction enzyme digestion followed by real-time 
quantitative assay to quantify plasma methylated KILLIN/PTEN DNA in these patients. Plasma 
levels of methylated KILLIN/PTEN DNA were significantly increased in these patients when 
compared with healthy controls (P,0.05). This study shows that plasma methylated KILLIN/
PTEN DNA was significantly elevated, suggesting hypermethylation of the KILLIN/PTEN 
promoter in breast and thyroid cancer patients.
Keywords: KILLIN, PTEN, hypermethylation, breast cancer, thyroid cancer
Introduction
Germline mutations in PTEN (phosphate and tensin homologue) have been reported 
to be associated with diseases such as Cowden syndrome (CS), and account for 80% 
of cases.1 CS is an autosomal dominant disorder characterized by multiple hamartoma 
syndromes, and is associated with an increased risk of developing breast, thyroid, and 
endometrial neoplasms.1 Individuals who met at least the relaxed International Cowden 
Consortium operational criteria were recruited. Relaxed criteria are defined as full 
criteria minus one criterion, and such individuals are referred to as CS-like. The life-
time risk of breast cancer in CS patients is estimated to be in the range of 25%–50%, 
with a pathological predominance of ductal and lobular carcinoma.1,2 Thyroid cancer 
is another common malignancy in patients with CS, with a lifetime risk of 10%, and 
the follicular-derived type is most often observed.1–3
The PTEN gene spans 105 kb and contains nine exons on chromosome 10q23.31. 
It is a well characterized tumor suppressor gene that antagonizes the phosphoinositol- 
3-kinase/protein kinase B (Akt) signaling pathway. The decreased level of phos-
phorylated Akt results in G1 cell cycle arrest and apoptosis.3,4 PTEN also regulates 
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interactions between the cell and extracellular matrix via 
interaction with focal adhesion kinase.5 In addition to CS, 
PTEN mutation is also reported in other hamartoma tumor 
syndromes, including Bannayan-Riley-Ruvalcaba syndrome, 
Proteus syndrome, and Proteus-like syndrome, as well as 
macrocephaly and autism.1,4,6
While the genetic predisposition of PTEN to multiple 
hamartoma syndromes in Caucasian populations is being 
increasingly understood, there are few relevant reports in 
Asian cohorts.7,8 Recent studies have reported a newly identi-
fied gene, KILLIN (RefSeq, NM_001126049), which is also 
located in the 10q23.31 chromosomal region,  proximal to 
PTEN. Similar to PTEN, KILLIN is involved in cell cycle 
arrest and is regulated by p53.9,10 Interestingly, PTEN and 
KILLIN share the same transcription start site, and are 
assumed to be regulated by the same promoter, but are tran-
scribed in opposite directions. Bennett et al recently demon-
strated that approximately 30% of CS and CS-like patients 
without PTEN mutations had germline hypermethylation 
and downregulation of the KILLIN gene.10 Therefore, in this 
study, we sought to determine if there is any association 
between KILLIN/PTEN genes in patients with breast and/or 
thyroid cancer. We also investigated whether KILLIN/PTEN 
promoter hypermethylation and downregulation were present 
in the plasma of Chinese patients.
Materials and methods
Patients
Twenty-three Chinese women with breast and/or thyroid 
cancer and a family history of thyroid cancer were recruited 
from the Hong Kong Hereditary Breast Cancer Family Reg-
istry between March 1, 2009 and February 28, 2011. We 
included four patients with breast cancer only, three patients 
with thyroid cancer only, and 16 patients with breast and 
thyroid cancer. In our study cohort, none of the patients with 
both breast and thyroid cancer had a family history of thyroid 
cancer. Twenty healthy control subjects with no diagnosed 
malignancy were also recruited for the study. Blood samples 
were collected from patients at diagnosis or during surgery. 
All patients were selected for Chinese ancestry and met the 
criteria for genetic/familial high-risk assessment according 
to the National Comprehensive Cancer Network. All the 
patients with breast cancer were confirmed to be BRCA1/2 
mutation-negative by direct bidirectional sequencing and 
by multiplex ligation-dependent probe amplification test-
ing.11,12 Written informed consent was obtained from all the 
participants, and the study was approved by the institutional 
review board of the University of Hong Kong/Hospital 
Authority West Cluster and other contributing hospitals in 
Hong Kong.
PTEN mutation screening  
by conventional Dna sequencing
Mutation screening was done by direct bidirectional DNA 
sequencing of all coding exons for PTEN and partial flank-
ing intronic sequences. All primer sequences are listed in 
Table S1. Mutation detection was performed on genomic 
DNA extracted from peripheral blood samples using a Qiagen 
DNA Mini blood kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. Bidirectional sequencing was 
performed using a BigDye® Terminator v3.1 cycle sequencing 
kit (Applied Biosystems, Foster City, CA, USA) and analyzed 
on an ABI 3130xl genetic analyzer (Applied Biosystems). 
The results of sequencing were compared with the reference 
DNA sequences using Variant Reporter software (Applied 
Biosystems) and then reviewed manually. Computational 
analysis for potential cryptic splice site mutation was per-
formed using splice site prediction programs (NNSPLICE 
and ESEF finder) when sequence changes were identified. 
All mutation and sequence variants were named according 
to the description of sequence variants as recommended by 
the Human Genome Variation Society.
rna extraction and real-time qPcr
Total RNA was extracted from whole blood using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Next, 0.5 µg of total RNA 
was reverse transcribed into cDNA using a high capac-
ity cDNA reverse transcription kit (Applied Biosystems). 
Real-time qPCR was performed using a QuantiTect SYBR 
Green PCR kit (Qiagen) in an ABI PRISM 7900 HT  system 
(Applied Biosystems). The sequences of the primers were 
as follows: PTEN-F, CAGAAAGACTTGAAGGCGTAT; 
PTEN-R, AACGGCTGAGGGAACTC; KILLIN-F: 
AAAAGAATTCCGGGGCTGGCGCTTGGGG;  KILLIN-R: 
AAAAGCGGCCGCGTCCTT TGGCTTGCTCTTAGG; 
GAPDH-F, GAAGGTGAAGGTCGGAGT; GAPDH-R, 
GAAGAT GGTGATGGGATTTC. Expression  levels 
of PTEN and  KILLIN mRNA were normalized to 
 glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Fold change in PTEN/KILLIN expression was calculated 
by the equation 2−∆∆Ct. ∆Ct was calculated by subtracting 
the Ct values of GAPDH from the Ct values of the genes. 
∆∆Ct was then calculated by subtracting ∆Ct of the control 
from ∆Ct of breast cancer. Real-time qPCR was performed 
in triplicate.
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Methylation-sensitive restriction  
enzyme digestion and MsreD-qPcr
Methylation-sensitive restriction enzyme digestion fol-
lowed by qPCR (MSRED-qPCR) assays were performed, 
as described previously.13 In brief, 100 ng of genomic DNA 
from either ethylenediaminetetraacetic acid blood or plasma 
samples was digested in a 40 µL reaction volume with 30 U 
of the methyl ation-sensitive restriction enzyme, BstU1 (New 
 England  BioLabs, Hitchin, UK) at 60°C for 16 hours. To ensure 
complete enzyme digestion, a positive and a negative control 
digestion containing 30 ng of completely methylated or unm-
ethylated control DNA (EpiTect Control DNA; Qiagen) were 
run in parallel. After digestion, the same amount of digested or 
undigested DNA along with control digestion was subjected 
to qPCR using a QuantiTect SYBR Green PCR kit in an 
ABI 7900 HT system. The primer sequence for the KILLIN/
PTEN promoter was F- GTTGTAGTTTTAGGGAGGGGGT; 
R-CTACTTCTCCTCAACAACCAAAAAC. Each reaction was 
performed in a final volume of 20 µL containing digested (1.3 
µL) or undigested (1 µL) DNA, 500 nM of each primer, and 1× 
SYBR Green PCR Master Mix (Qiagen). At the end of the PCR 
cycles, melting curve analyses were performed to validate the 
specific PCR product. Relative expression of methylated DNA 
was expressed as 2∆Ct(undigest-digest). ∆Ct
(undigest-digest)
 was calculated 
by subtracting the Ct values of plasma DNA from the Ct values 
of undigested DNA. Given that the Ct of undigest should be less 
than or equal to the Ct of digest, the expression level ranged from 
1 to 0. Each sample was run in duplicate for analysis. For 100% 
digestion efficiency, the relative expression level of completely 
unmethylated control (CTRL) DNA (2∆Ct(CTRLundigest-CTRLdigest)) 
must be close to zero, whereas the level of completely methylated 
control must be 1.
statistical analysis
The significance of PTEN and KILLIN expression levels in 
blood was determined using the Mann–Whitney U test. The 
statistical significance of plasma methylated KILLIN DNA 
levels was also determined by the Mann–Whitney U test. The 
correlation between PTEN and KILLIN gene expression was 
determined by Spearman’s rank correlation coefficient. All 
P-values were two-sided and a value ,0.05 by GraphPad 
Prism 5 software (GraphPad Software, La Jolla, CA, USA) 
was considered to be statistically significant.
Results
Patient characteristics
A total of 23 patients with breast and/or thyroid cancer were 
recruited. The mean age at diagnosis of breast cancer was 
51.4 (range 33–74) years and that of thyroid cancer was 43.84 
(range 19–74) years. The mean age of the healthy controls 
was 49.7 years. The patient characteristics were shown in 
Table 1.
PTEN mutation screening  
by full gene sequencing
Based on our PTEN sequencing results, no PTEN  coding 
mutations were found. Only four single nucleotide 
polymorphisms were identified, including c.1–9C.G, 
c.80–96A.G, c.1026+32T.G, and c.1212+75T.A, which 
were reported in the Single Nucleotide Polymorphism Data-
base of the National Center of Biotechnology Information 
(Table 2).
Downregulated expression  
of Killin but not PTen
We examined the expression levels of PTEN and KILLIN 
using qPCR in blood samples from 23 patients and 20 healthy 
controls. Our results show that PTEN gene  expression was 
higher in cancer patients when compared with healthy controls 
(Figure 1A). On the other hand,  expression of KILLIN was sig-
nificantly decreased in patients when compared with healthy 
controls (Figure 1B). However, there is no direct correlation 
between PTEN and KILLIN mRNA expression (Figure 1C). 
Interestingly, when we stratified patients into those with breast 
cancer only, thyroid cancer only, and both breast cancer and 
thyroid cancer, the expression level of PTEN was significantly 
increased in those with breast cancer and thyroid cancer, and 
in those with breast cancer only, when compared with healthy 
controls (Figure 2A). Also, there was a decreasing trend of 
KILLIN expression levels in patients with breast cancer and 
thyroid cancer, those with breast cancer only, and those with 
thyroid cancer only relative to healthy controls (Figure 2B).
Quantitative analysis of methylated  
KILLIN Dna in the plasma of patients
To investigate whether downregulation of expression is associ-
ated with hypermethylation of the KILLIN/PTEN promoter, 
we developed a simple methylation-sensitive restriction 
enzyme digestion and real-time quantitative assay to quantify 
the methyl ated KILLIN DNA in the patients’ blood samples. 
Initially, methyl ated KILLIN DNA levels in blood samples 
from the 23 patients and 20 healthy controls were assessed. 
Our results indicated that there was no significant difference in 
blood levels of methylated DNA between cancer patients and 
healthy controls (P=0.111; Figure 3A). We also assessed the 
level of methylated KILLIN/PTEN DNA in the plasma samples. 
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Our results demonstrated that plasma levels of methylated 
KILLIN DNA in the 23 cancer patients were significantly 
increased when compared with those in controls (P,0.05; 
Figure 3B), suggesting hypermethylation of the KILLIN/PTEN 
promoter in these patients, and significant negative correlation 
between blood level of KILLIN mRNA expression and plasma 
level of methylated KILLIN DNA of the 43 subjects including 
20 healthy controls and 23 cancer patients (Spearman r=–0.58, 
P,0.0001; Figure 4).
Discussion
In this study, we found that KILLIN gene expression but not 
that of PTEN, was significantly decreased in blood samples 
from Chinese women with breast and/or thyroid cancers. 
We then quantified plasma methylated KILLIN/PTEN DNA 
levels in these patients and demonstrated that they were sig-
nificantly elevated. To the best of our knowledge, this is the 
first report to show increased plasma levels of methylated 
KILLIN DNA in such patients, suggesting hypermethylation 
of the KILLIN/PTEN promoter in breast and thyroid cancer.
Given that variants c.80–96A.G, c.1026+32T.G, and 
1212+75T.A were identified in most of our subjects and 
the fact that they were located far away from the PTEN 
exons, these variants might be presumed to have no effect 
on normal PTEN function.2 It is unclear whether variant 
c.1–9C.G would have any effect on PTEN expression 
in breast and thyroid carcinoma. This variant is shown in 
the Single Nucleotide Polymorphism Database from the 
National Centre of  Biotechnology Information with a noted 
frequency of 0.024, and has not been reported in carcinoma. 
However, overexpression of PTEN has been shown to be 
associated with this variant in type 2 diabetes in the Japanese 
population.7 The nucleotide sequence around the AUG 
initiation codon can influence recognition of the ribosome 
and affect the efficiency of translation. It was suggested that 
Table 1 Patient characteristics
Case number Age at diagnosis  
of BC, years
BC type Family history 
of BC
Age at diagnosis  
of TC, years
TC type Family history 
of TC
Bc and Tc
 PMh1301 33 iDc no 21 colloid nodule na
 TWh51701 40 iDc + ilc na 26 FTc na
 TWh51901 47 iDc no 35 FTc na
 TWh49701 42 iDc no 43 na no
 PTen201 35 Dc no 44 PTc no
 PTen901 64 iDc na 46 FTc na
 PTen1101 74 iDc na 57 FTc na
 hKsh1101 51 iDc + ilc na 60 PTc na
 PTen1001 66 na no 70 PTc no
 PTen101 70 iDc Yes 70 PTc na
 Uch701 73 iDc no 74 Medullary na
 Uch201 38 iDc no 38 PTc na
 Qeh601 52 iDc na 52 PTc no
 QMh7801 71 Dcis no 20 na no
 TWh42301 38 iDcii (l); Dcis (r) no 38 PTc no
 TWh56201 50 iDcii na 42 PTc na
Tc only
 TWh46303 not applicable not applicable na 19 PTc Yes
 TWh46302 not applicable not applicable na 44 PTc Yes
 TWh36401 not applicable not applicable Yes 34 PTc na
Bc only
 TWh36901 40 iDc no not applicable not applicable Yes
 TWh4101 44 iDc Yes not applicable not applicable Yes
 TWh46301 50 iDc (l); Dcis (r) no not applicable not applicable Yes
 TWh50901 50 iDc na not applicable not applicable Yes
Abbreviations: Bc, breast cancer; Tc, thyroid cancer; na, not available; iDc, invasive ductal carcinoma; Dcis, ductal carcinoma in situ; ilc, invasive lobular carcinoma; 
Dc, ductal carcinoma; PTc, papillary thyroid carcinoma; FTc, follicular thyroid carcinoma; (l), left breast; (r), right breast; PMh, Princess Margaret hospital; TWh, Tung 
Wah hospital; hKsh, hong Kong sanatorium and hospital; Uch, United christian hospital; Qeh, Queen elizabeth hospital; QMh, Queen Mary hospital.
Table 2 PTEN polymorphisms in patients with cancer of the 
breast and/or thyroid
Location Variant NCBI ref SNP
5′UTr c.1–9c.g rs11202592
intron 1 c.80–96a.g rs1903858
intron 8 c.1026+32T.g rs555895
intron 9 c.1212+75T.a rs74535369
Abbreviations: ncBi, national center of Biotechnology information; ref, reference; 
snP, single nucleotide polymorphism; UTr, untranslated region.
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substitution of the G residue at position 9 results in greater 
homology of the PTEN gene sequence, ctcccagacATGa, to 
the Kozak sequence gccgcc(a/g)ccATGg, which has been 
reported to enhance translation in mammalian cells.7,14 The 
prevalence of c.1–9C.G in diabetic patients was reported to 
be 14% (15/107) for both the heterozygous and homozygous 
variants, whereas only 5% (5/100) of control subjects car-
ried the heterozygous variant but not the homozygous vari-
ant.7 In our study, three of 18 (16.6%) patients carried the 
heterozygous variant and no homozygous variant was found. 
Due to the small sample size and lack of comparison with 
control subjects, no association between the polymorphism 
and our cancer patients could be identified. The pathoge-
nicity of this variant in breast and thyroid cancers remains 
to be elucidated and confirmed by protein expression and 
functional assays. However, the broad phenotypic spectrum 
of multiple hamartoma syndromes makes diagnosis of CS 
complicated, and hence recruitment of suitable subjects for 
research is difficult.1,2,6,15–17 CS-like patients, with features 
of CS but not meeting the strict diagnostic criteria, might 
not have PTEN mutation.2,6,16 Although breast and thyroid 
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Figure 1 PTEN and KILLIN expression in cancer patients.
Notes: gene expression of (A) PTEN and (B) KILLIN in blood samples from healthy 
normal subjects (n=20) and patients with cancer of the breast and/or thyroid (n=23). 
expression of mrna was normalized to GAPDH. The lines inside the boxes denote 
the medians. The boxes mark the interval between the 25th and 75th percentiles. 
The whiskers denote the interval between the 10th and 90th percentiles. statistical 
significance of differences was analyzed using Mann–Whitney U tests. (C) correlation 
between PTEN and KILLIN mrna expression (spearman rank correlation, r=−0.06, 
P=NS, not significant).
Abbreviations: ncBi, national center of Biotechnology information; snP, single 
nucleotide polymorphism.
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Figure 2 expression levels of PTEN and KILLIN in patients with breast and thyroid 
cancer.
Notes: gene expression of (A) PTEN and (B) KILLIN in blood samples from healthy 
normal subjects (n=20), and patients with breast and thyroid cancer (n=16), breast 
cancer only (n=4), and thyroid cancer only (n=3).
Abbreviations: Bc, breast cancer; Tc, thyroid cancer.
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cancers are the most common manifestation of CS, renal cell 
and endometrial carcinoma could be included in the patient 
selection criteria to increase the chances of finding PTEN 
mutations.6,8,16–18 In addition to the coding region, it is sug-
gested that the promoter region is an important site of PTEN 
analysis. A screen of 119 CS patients negative for PTEN 
mutation at the coding region showed that 10% had mutations 
located at the promoter region between −1344 and −745 bp 
upstream of the translation start codon.4 It was estimated that 
mutations at the promoter might result in post-translational 
modifications or targeted PTEN degradation, thereby lead-
ing to impaired protein expression.4 Other than PTEN, 
succinate dehydrogenase genes might be alternative markers 
for CS/CS-like syndromes.6,17 Succinate dehydrogenase 
is a mitochondrial enzyme complex that participates in the 
electron transport chain and Kreb’s cycle. Like PTEN, suc-
cinate dehydrogenase also has a tumor suppressor function, 
and negatively regulates the Akt and mitogen-activated 
protein kinase signaling pathway.19 One study showed that 
13.5% of PTEN mutation-negative CS/CS-like patients 
had germline succinate dehydrogenase complex subunit B 
(SDHB) and succinate dehydrogenase complex subunit D 
(SDHD) mutations.6 Patients with succinate dehydrogenase 
mutations had increased levels of phosphorylated Akt and 
mitogen-activated protein kinase, causing dysregulation of 
apoptosis. Higher frequencies of breast, thyroid, and renal 
cell carcinomas were observed in succinate dehydrogenase 
mutation carriers than PTEN mutation carriers.6
Apart from PTEN, KILLIN is another important gene that 
might be implicated in breast cancer. One recent study offers 
an intriguing explanation for some of the families with PTEN 
wild-type CS and Cowden-like syndrome.10 The authors of 
that study examined peripheral lymphocytes from patients 
with CS or Cowden-like syndrome for hypermethylation of 
the PTEN promoter.10  Unexpectedly, they discovered that 
although a significant proportion of patients had hyperm-
ethylation of the PTEN promoter, silencing of PTEN was 
not found. Bennett et al investigated a relatively new gene 
known as KILLIN.  KILLIN has recently been identified and 
little is known about its function or its role in cancer. They 
found that KILLIN is indeed transcribed in the opposite, 
ie, antisense, strand relative to PTEN and shares the same 
promoter as PTEN. Thus, they postulated that the methyla-
tion changes in their patient samples were indeed regulating 
KILLIN expression and not that of PTEN. They demonstrated 
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Figure 3 Methylated KILLIN Dna expression in plasma samples from healthy 
normal subjects and patients with breast and/or thyroid cancer.
Notes: Quantitative analysis of methylated KILLIN/PTEN Dna in (A) blood samples 
from healthy normal subjects (n=20) and patients (n=23) and in (B) plasma samples 
by methylation-sensitive restriction enzyme digestion followed by qPcr. scatter 
plots for plasma levels of methylated KILLIN Dna in healthy normal subjects (n=20) 
and patients with breast and thyroid cancer (n=16), breast cancer (n=4), and thyroid 
cancer (n=3). Horizontal lines denote the medians. Statistically significant differences 
were determined using the Mann–Whitney U test, P,0.0001.
Abbreviations: Bc, breast cancer; qPcr, quantitative polymerase chain reaction; 
Tc, thyroid cancer.
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patients (spearman rank correlation, r=−0.58, P,0.0001).
OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2091
hypermethylation of KILLIN/PTEN in cancer patients
that patients with KILLIN/PTEN promoter hypermethylation 
have significantly reduced KILLIN gene expression levels 
compared with controls.10 Since there is only an association 
between  downregulated KILLIN  expression and hyper-
methylation of the KILLIN/PTEN promoter, PTEN expres-
sion was not affected by promoter hypermethylation. We 
speculate that other regulatory mechanisms may be involved 
in PTEN expression, specifically in the development of 
breast cancer.
We believe that our finding of increased plasma methy-
lated KILLIN/PTEN DNA in patients with thyroid and breast 
cancers relative to those with either of these cancers alone 
might have important clinical implications. One possible 
clinical scenario would be if a female patient has been 
diagnosed with a follicular-derived thyroid carcinoma and 
is also found to have raised plasma methylated KILLIN/
PTEN DNA. Our results suggest that such a patient has 
a relatively higher chance of developing breast cancer in 
the future and so would benefit from breast cancer screen-
ing. In other words, methylated KILLIN/PTEN DNA in 
plasma could be used as a diagnostic marker for patients 
with an increased lifetime risk of developing both cancers. 
 However, a much larger longitudinal study would be needed 
to confirm this.
Conclusion
Taken together, no correlation between PTEN mutations 
and cancer of the breast and/or thyroid was found in this 
study. Nonetheless, hypermethylation of the KILLIN/PTEN 
promoter could have contributed to the development of 
these cancers in those patients without identifiable PTEN 
mutations. In this regard, we showed that plasma methylated 
KILLIN/PTEN DNA was significantly increased, suggesting 
hypermethylation of the KILLIN/PTEN promoter in patients 
with breast and/or thyroid cancers. Because our sample 
size was small, further validation in a larger sample size is 
required to confirm the potential diagnostic usefulness of 
this methylated DNA marker.
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Table S1 sequence of polymerase chain reaction and sequencing primers for PTEN gene
Exon Forward primer sequence (5′ to 3′) Reverse primer sequence (5′ to 3′)
1 aTTTccaTccTgcagaagaagc gcaaccaggcaagagTTccgT
2 TTTaTTacTccagcTaTagTggg ccaTTaggTacggTaagccaaa
3 ccaTagaaggggTaTTTgTTgg ggacTTcTTgacTTaaTcggTTT
4 TaaacacagcaTaaTaTgTgTcac aTgTaTcTcacTcgaTaaTcTgg
5 TTaagTTTgTaTgcaacaTTTcTa gTaTaTacacaTacaTcaaaacaTc
6 gTaTaTaTgTTcTTaaaTggcTa cTTcagaaaTaTagTcTccTgcaT
7 gaTacagaaTccaTaTTTcgTgTa gTaagcaaaacaccTgcagaTc
8 caaaTgTTTaacaTaggTgacaga cTgcTacgTaaacacTgcTTcga
8s gacaaaaTgTTTcacTTTTgggT
9 TaaagaTcaTgTTTgTTacagTgc TcTgacacaaTgTccTaTTgcc
9s TTcaTggTgTTTTaTcccTcTTg
Abbreviation: s, sequencing primer.
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